|
Glenmark Pharmaceuticals Ltd.
|
Income Statement
|
|
|
You can view the
Income Statement
for the last 5 years.
|
Market Cap. (Rs.)
|
70979.51 Cr.
|
P/BV
|
6.46
|
Book Value (Rs.)
|
389.58
|
|
52 Week High/Low (Rs.)
|
2538/1793
|
FV/ML
|
1/1
|
P/E(X)
|
52.12
|
|
Bookclosure
|
31/08/2026
|
EPS (Rs.)
|
48.25
|
Div Yield (%)
|
0.20
|
|
(Rs. in Crs.)
| Months | 12 | 12 | 12 | 12 | 12 |
| Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR | AR | AR |
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| | | | | | |
| | | | | | |
| INCOME | | | | | |
| Revenue From Operations [Net] | 16711.40 | 13145.84 | 11813.10 | 12725.43 | 12174.20 |
| Other Operating Revenues | 271.11 | 175.90 | 0.00 | 264.68 | 130.71 |
| Total Operating Revenues | 16982.51 | 13321.74 | 11813.10 | 12990.11 | 12304.90 |
| | | | | | |
| Other Income | 460.62 | 113.72 | 839.99 | 316.79 | 166.67 |
| Total Revenue | 17443.13 | 13435.46 | 12653.09 | 13306.90 | 12471.58 |
| | | | | | |
| EXPENSES | | | | | |
| Cost Of Materials Consumed | 2961.46 | 3001.27 | 3157.82 | 3593.79 | 3278.76 |
| Purchase Of Stock-In Trade | 2396.64 | 1566.00 | 1451.17 | 1268.26 | 1117.67 |
| Operating And Direct Expenses | 146.02 | 89.54 | 0.00 | 0.00 | 74.42 |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -610.64 | -213.93 | -195.62 | -325.09 | -11.14 |
| Employee Benefit Expenses | 3577.85 | 3022.06 | 2868.14 | 2780.96 | 2447.42 |
| Finance Costs | 208.73 | 207.07 | 515.97 | 349.58 | 298.10 |
| Depreciation And Amortisation Expenses | 573.48 | 486.01 | 581.91 | 611.27 | 486.72 |
| Other Expenses | 3938.76 | 3505.42 | 3336.25 | 3393.83 | 3077.48 |
| Total Expenses | 13192.30 | 11663.43 | 11715.64 | 11672.59 | 10769.42 |
| | | | | | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 4250.83 | 1772.03 | 937.45 | 1634.31 | 1702.16 |
| | | | | | |
| Exceptional Items | -2266.08 | -372.82 | -900.96 | -765.85 | -260.91 |
| Profit/Loss Before Tax | 1984.75 | 1399.21 | 36.50 | 868.45 | 1441.25 |
| | | | | | |
| Tax Expenses-Continued Operations | | | | | |
| Current Tax | 676.49 | 382.34 | 1115.55 | 566.90 | 546.65 |
| Deferred Tax | -53.69 | -30.27 | 751.79 | -75.85 | -99.05 |
| Total Tax Expenses | 622.79 | 352.07 | 1867.35 | 491.05 | 447.60 |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1361.95 | 1047.14 | -1830.85 | 377.40 | 993.65 |
| | | | | | |
| Profit/Loss From Continuing Operations | 1361.95 | 1047.14 | -1830.85 | 377.40 | 993.65 |
| | | | | | |
| Profit/Loss From Discontinuing Operations | 0.00 | 0.00 | 397.33 | 0.00 | 0.00 |
| Net Profit/Loss From Discontinuing Operations | 0.00 | 0.00 | 397.33 | 0.00 | 0.00 |
| Profit/Loss For The Period | 1361.95 | 1047.14 | -1433.52 | 377.40 | 993.65 |
| | | | | | |
| Minority Interest | -0.10 | -0.05 | -68.15 | -80.16 | -51.94 |
| Consolidated Profit/Loss After MI And Associates | 1361.85 | 1047.10 | -1501.67 | 297.25 | 941.71 |
| | | | | | |
| OTHER INFORMATION | | | | | |
| | | | | | |
| EARNINGS PER SHARE | | | | | |
| Basic EPS (Rs.) | 48.26 | 37.11 | -53.22 | 10.53 | 33.37 |
| Diluted EPS (Rs.) | 48.24 | 37.11 | -53.22 | 10.53 | 33.37 |
| | | | | | |
| DIVIDEND AND DIVIDEND PERCENTAGE | | | | | |
| Equity Share Dividend | 141.10 | 70.55 | 70.54 | 70.54 | 70.54 |
